(Adnkronos) - “Il farmaco viene somministrato in maniera ottimale per i nostri pazienti, perché è un farmaco orale - spiega Gasperini - abbiamo una somministrazione di due settimane in un mese, dopo il paziente non assume più il farmaco per un anno. Si ripete poi questo ciclo l'anno successivo e per quattro anni, se il paziente è rispondente, è libero da qualunque tipo di terapia, ma soprattutto è libero da attività di malattia”. Lo ha detto Claudio Gasperini, direttore dell'Uoc di Neurologia dell’ospedale San Camillo di Roma e coordinatore del Gruppo di studio della Sclerosi multipla della Società Italiana di Neurologia, in occasione della consegna del Premio innovazione digitale in neurologia, giunto alla sua sesta edizione e consegnato da Merck nel corso del 54° Congresso della Società italiana di neurologia (Sin), in svolgimento a Roma fino al 12 novembre.
Category
🗞
NewsTranscript
00:00What is cladribine?
00:04Cladribine is an innovative and very interesting mechanism
00:08that we define as immune-replacing.
00:11What does immune-replacing mean?
00:13It means that the drug is able to kill
00:17lymphocytes B and T,
00:19which are the ones that subsequently attack myelin
00:22and therefore determine the tissue damage
00:24and the progression of disability.
00:26After the assumption of cladribine,
00:28lymphocytes B and T tend to be significantly reduced
00:34and cladribine begins to rebuild new lymphocytes B and T
00:39that in theory do not have memory against myelin
00:42and therefore we are able, over time,
00:44to control the aggression of these cells on myelin
00:49and to control the progression of disability.
00:51The drug is optimally supplied to our patients
00:55because it is a choral drug.
00:57The drug is administered for two weeks in a month,
01:00after which the patient no longer takes the drug for a year,
01:03repeats this cycle the following year
01:05and for four years, if the patient is responsive,
01:08he is free from any type of therapy
01:11but above all he is free from disease activities
01:14because in addition to the beauty of drug administration,
01:18the impact on the effectiveness
01:21and safety of our patients is also important.
01:24In this symposium, we presented the four-year data
01:28from the MAGNIFY study,
01:30which shows how about 80% of patients
01:33are free from progression of disability in the motor sense,
01:36in the sense of absence of new lesions of the magnetic resonance,
01:39in the sense of good control of the cognitive deficit
01:42and therefore this means guaranteeing a stabilization of the disease
01:46in a large part of our patients.
01:48In addition to this, there is a very important safety data,
01:51however, there are no warnings of attention,
01:54our patients have not had significant side effects
01:57and this allows us to use this drug
02:00also in the older age group of our patients,
02:03over 50 years old,
02:05in which the issue of immunosubstance
02:07determines the reduction of immune defenses.
02:10Well, with the drug it has been shown in a post hoc analysis
02:13that even in these patients there are no side effects.
02:16So it is a drug that we can use
02:18both in the very early stage of the disease in young patients
02:21but also in those patients
02:23in which the disease manifests itself in old age
02:26or they are patients who no longer respond
02:29in an already more advanced age
02:31and therefore even there it is certainly a positioning of the drug
02:34that helps us to control the evolution of the disease in our patients.